Gentry Leesa 4
4 · RenovoRx, Inc. · Filed Mar 8, 2024
Insider Transaction Report
Form 4
RenovoRx, Inc.RNXT
Gentry Leesa
Chief Clinical Officer
Transactions
- Award
Options
2024-03-06+190,000→ 190,000 totalExercise: $1.69→ Common Stock (190,000 underlying)
Footnotes (1)
- [F1]Represents 10-year incentive stock options to purchase 190,000 shares of the Company's common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan. These options vest over four years at a rate of 1/48 per month, beginning to vest on March 1, 2024.